Avant Diagnostics is a diagnostic company mainly focused on the commercialization of OvaDx, a proprietary microarray-based diagnostic test for the early detection of ovarian cancer. Pre-clinical research studies with OvaDx indicate high sensitivity and specificity for all types and stages of ovarian cancer. Upon FDA 510K approval, Avant Diagnostics intends to sell or license OvaDx as a diagnostic test for women seeking greater wellness and for women in the elevated risk category for ovarian cancer. Avant intends to utilize its public company stage to expand its portfolio of diagnostic tests in the future. For more information, visit the company’s website at www.avantdiagnostics.com